NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free INMB Stock Alerts $11.63 -0.25 (-2.10%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$11.37▼$12.1950-Day Range$10.53▼$14.0152-Week Range$5.87▼$14.74Volume92,870 shsAverage Volume65,171 shsMarket Capitalization$209.57 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get INmune Bio alerts: Email Address INmune Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside37.6% Upside$16.00 Price TargetShort InterestBearish12.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.84 out of 5 starsMedical Sector859th out of 939 stocksBiological Products, Except Diagnostic Industry144th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, INmune Bio has a forecasted upside of 37.6% from its current price of $11.63.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.28% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 18.7, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 3.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INMB. Previous Next 1.9 News and Social Media Coverage News SentimentINmune Bio has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for INmune Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About INmune Bio Stock (NASDAQ:INMB)INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More INMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMB Stock News HeadlinesMarch 26, 2024 | globenewswire.comINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28March 26, 2024 | americanbankingnews.comINmune Bio (NASDAQ:INMB) Stock Price Down 4%March 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 13, 2024 | globenewswire.comINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyMarch 6, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment DevelopmentsMarch 5, 2024 | globenewswire.comINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™February 17, 2024 | finance.yahoo.comINMB Jun 2024 25.000 callMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 16, 2024 | finance.yahoo.comINMB Mar 2024 20.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 12.500 putFebruary 15, 2024 | finance.yahoo.comINMB Feb 2024 15.000 putFebruary 12, 2024 | finance.yahoo.comINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 7, 2024 | finance.yahoo.comINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024February 4, 2024 | finance.yahoo.comInsiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the companyFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic ApproachFebruary 1, 2024 | msn.comInmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 EnrollmentJanuary 31, 2024 | msn.comFDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trialJanuary 31, 2024 | markets.businessinsider.comInmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program DevelopmentsJanuary 31, 2024 | es.investing.comINmune Bio Inc (INMB)January 31, 2024 | bizjournals.comFDA lifts hold on local company's clinical trial for Alzheimer's drugJanuary 30, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease ProgramJanuary 30, 2024 | marketwatch.comFDA Lifts Clinical Hold on INmune Bio Alzheimer's ProgramJanuary 30, 2024 | tmcnet.comINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease ProgramJanuary 30, 2024 | markets.businessinsider.comINmune Bio: FDA Removes Clinical Hold For Alzheimer's Disease ProgramJanuary 30, 2024 | finance.yahoo.comINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease ProgramJanuary 24, 2024 | finance.yahoo.comELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologySee More Headlines Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/28/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+37.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,300,000.00 Net Margins-12,246.88% Pretax Margin-12,246.88% Return on Equity-52.26% Return on Assets-38.08% Debt Debt-to-Equity Ratio0.05 Current Ratio3.18 Quick Ratio3.18 Sales & Book Value Annual Sales$370,000.00 Price / Sales566.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book3.47Miscellaneous Outstanding Shares18,020,000Free Float11,516,000Market Cap$209.57 million OptionableOptionable Beta1.99 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Raymond Joseph Tesi M.D. (Age 68)Co-Founder, President, CEO, Chief Medical Officer & Chairman Comp: $591.5kMr. David J. Moss M.B.A. (Age 54)CFO, Treasurer & Secretary Comp: $445.16kDr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer Comp: $152.01kMr. Joshua S. Schoonover Esq.General CounselKey CompetitorsVaxartNASDAQ:VXRTCompugenNASDAQ:CGENOptheaNASDAQ:OPTAcumen PharmaceuticalsNASDAQ:ABOSAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 9,251 shares on 3/11/2024Ownership: 3.004%Vanguard Group Inc.Sold 9,251 shares on 2/15/2024Ownership: 3.004%Citadel Advisors LLCSold 4,400 shares on 2/15/2024Ownership: 0.000%Royal Bank of CanadaSold 14,892 shares on 2/14/2024Ownership: 0.321%Balyasny Asset Management L.P.Bought 23,258 shares on 2/14/2024Ownership: 0.129%View All Insider TransactionsView All Institutional Transactions INMB Stock Analysis - Frequently Asked Questions Should I buy or sell INmune Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares. View INMB analyst ratings or view top-rated stocks. What is INmune Bio's stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for INmune Bio's shares. Their INMB share price targets range from $16.00 to $16.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts price targets for INMB or view top-rated stocks among Wall Street analysts. How have INMB shares performed in 2024? INmune Bio's stock was trading at $11.26 at the beginning of 2024. Since then, INMB shares have increased by 3.3% and is now trading at $11.63. View the best growth stocks for 2024 here. When is INmune Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our INMB earnings forecast. How can I listen to INmune Bio's earnings call? INmune Bio will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13744427". How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.12. The company earned $0.01 million during the quarter. INmune Bio had a negative net margin of 12,246.88% and a negative trailing twelve-month return on equity of 52.26%. During the same quarter in the prior year, the company earned ($0.36) EPS. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX). Who are INmune Bio's major shareholders? INmune Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Janney Montgomery Scott LLC (0.91%), Royal Bank of Canada (0.32%), UBS Group AG (0.24%) and Fermata Advisors LLC (0.16%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INMB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.